Provided by Tiger Fintech (Singapore) Pte. Ltd.

Editas Medicine

1.79
-0.2650-12.93%
Volume:2.75M
Turnover:5.04M
Market Cap:147.35M
PE:-0.70
High:2.02
Open:1.94
Low:1.72
Close:2.05
Loading ...

Cautious Outlook for Editas Medicine Amid Strategic Shift and Competitive Challenges

TIPRANKS
·
13 Dec 2024

Editas Medicine downgraded to Hold from Buy at Stifel

TIPRANKS
·
13 Dec 2024

Editas Medicine: Navigating Uncertainty with a Hold Rating Amid Strategic Shifts and Development Challenges

TIPRANKS
·
13 Dec 2024

Editas Medicine Focuses on In Vivo Gene-Editing Medicines, Ends Reni-Cel Development to Cut Costs

MT Newswires Live
·
13 Dec 2024

BRIEF-Editas Medicine Announces Strategic Transition To In Vivo Gene Editing Company

Reuters
·
13 Dec 2024

Editas Medicine Pivots Gene Editing Strategy, Cutting 65% of Workforce

Dow Jones
·
13 Dec 2024

Editas Medicine Inc - Expected Costs of $55 Million to $70 Million

THOMSON REUTERS
·
13 Dec 2024

Editas Medicine Inc - Discontinues Clinical Development of Reni-Cel Program

THOMSON REUTERS
·
13 Dec 2024

Editas Medicine Inc - Chief Medical Officer Baisong MEI to Step Down Effective Dec 31, 2024

THOMSON REUTERS
·
13 Dec 2024

Editas to reduce about 65% of its workforce over the next six months

Reuters
·
13 Dec 2024

Editas Medicine Inc: Initiating Cost Savings Measures and Reduction in Headcount to Align Workforce

THOMSON REUTERS
·
13 Dec 2024

Editas Medicine Inc: Jessica Hopfield, Has Been Named Chair of Board, Effective December 31

THOMSON REUTERS
·
13 Dec 2024

Editas Medicine Inc - Initiated Reduction in Headcount to Eliminate Approximately 65% of Its Workforce Over Next Six Months

THOMSON REUTERS
·
13 Dec 2024

Editas Medicine Inc: Intends to Share Pre-Clinical Data and Further Development Timelines From These Programs in Q1 of 2025

THOMSON REUTERS
·
13 Dec 2024

Editas Medicine Announces Strategic Transition to in Vivo Gene Editing Company With Intent to Achieve Human Proof of Concept in Approximately Two Years

THOMSON REUTERS
·
13 Dec 2024

Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

GlobeNewswire
·
13 Dec 2024